8-K: BioLife Solutions Reports Q1 2024 Results, Highlights Strategic Realignment and Divestiture

BioLife Solutions announced its first quarter 2024 financial results, showcasing a 10% sequential increase in cell processing revenue and the divestiture of its GCI freezer business.

Summary

• BioLife Solutions reported a total revenue of $31.7 million for the first quarter of 2024, a 16% decrease compared to the same period last year.
• Cell processing revenue saw a 10% sequential increase, reaching $16.2 million, while freezer and thaw systems revenue decreased by 35% year-over-year to $8.4 million.
• The company's GAAP gross margin was 38%, with a net loss of $10.2 million.
• Excluding the divested GCI freezer business, the adjusted gross margin improved to 53% and adjusted EBITDA was $3.6 million.
• BioLife Solutions affirmed its 2024 revenue guidance of $95.5 million to $100.0 million, focusing on cell processing and biostorage services.
• The company processed 22 new U.S. FDA Master File cross references for its biopreservation media, bringing the cumulative total to 716.
• BioLife's biopreservation media is now embedded in 15 unique commercial CGTs, with an expectation of 11 additional approvals or expansions in the next 12 months.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strategic divestiture and improved adjusted financials, but tempered by the year-over-year revenue decline and net loss.

Positives

• The cell processing platform showed strong sequential growth of 10% in revenue.
• The divestiture of the GCI freezer business has significantly improved the company's financial metrics.
• The adjusted gross margin and adjusted EBITDA improved substantially after excluding the GCI business.
• The company's biopreservation media is widely used in the CGT industry, supporting over 70% of relevant trials.
• BioLife Solutions is affirming its 2024 revenue guidance, indicating confidence in future performance.
• The company is seeing increased product approvals and geographic expansions in the CGT market.

Negatives

• Total revenue decreased by 16% year-over-year to $31.7 million.
• The company reported a GAAP net loss of $10.2 million for the quarter.
• Freezer and thaw systems revenue decreased by 35% year-over-year.
• The company's GAAP gross margin was 38%, which is lower than the adjusted non-GAAP margin.
• The company had a negative adjusted EBITDA of $1.2 million when including the GCI business.

Risks

• The company's total revenue decreased year-over-year, indicating potential challenges in overall growth.
• The company is still working to finalize the sale of its remaining freezer asset, CBS, which could pose further challenges.
• The company is reliant on the CGT market, which is subject to regulatory and market fluctuations.
• The company's GAAP net loss of $10.2 million indicates ongoing financial challenges.
• The company's cash, cash equivalents, and marketable securities decreased to $46.1 million from $52.3 million at the end of 2023.

Future Outlook

BioLife Solutions is affirming its 2024 revenue guidance of $95.5 million to $100.0 million and expects full year positive adjusted EBITDA and adjusted EBITDA growth in 2024, focusing on cell processing and biostorage services.

Management Comments

• We are off to a solid start to 2024, delivering another quarter of sequential core cell processing revenue platform growth while advancing our strategic realignment to concentrate on our most valuable franchises.
• In April, we executed a key objective with the divestiture of the Global Cooling, Inc. (GCI) freezer business, immediately transforming our financial profile.
• While there is still work to do, including finalizing the sale process of our remaining freezer asset, Custom Biogenic Systems (CBS), we believe that the Company is already in a much healthier position seeing the operating leverage of our high-margin consumable offering as it becomes the main contributor to total sales.
• In the first quarter, our core cell processing platform posted a 10% sequential increase in revenue, affirming our belief that the industry-wide recovery that began at the end of last year is progressing forward.

Industry Context

This announcement reflects a strategic shift for BioLife Solutions, focusing on its core cell processing and biostorage services while divesting its freezer business. This move aligns with the growing demand for cell and gene therapy solutions and the company's focus on high-margin consumables. The company's biopreservation media is a key component in the CGT industry, and the company is well-positioned to benefit from the increasing number of product approvals and geographic expansions in this sector.

Comparison to Industry Standards

• BioLife Solutions' 10% sequential growth in cell processing revenue is a positive sign, indicating a recovery in the industry, which is in line with other companies in the cell and gene therapy space.
• The divestiture of the GCI freezer business and the resulting improvement in adjusted gross margin to 53% is a significant step towards profitability, which is a key focus for many companies in the biotech sector.
• The company's biopreservation media being embedded in 15 commercial CGTs and the expectation of 11 more approvals in the next 12 months demonstrates a strong market position, which is comparable to other leading suppliers in the industry.
• The affirmation of 2024 revenue guidance of $95.5 million to $100.0 million is a positive signal, indicating confidence in future performance, which is a key metric for investors in the biotech industry.

Stakeholder Impact

• Shareholders will likely react positively to the improved adjusted financials and strategic focus, but negatively to the year-over-year revenue decline and net loss.
• Employees may experience changes due to the divestiture of the freezer business and the company's strategic realignment.
• Customers will continue to benefit from the company's cell processing and biostorage services.
• Suppliers may see changes in demand based on the company's strategic focus.
• Creditors will be monitoring the company's financial performance and cash position.

Next Steps

• The company will continue to focus on its cell processing and biostorage services platforms.
• BioLife Solutions will finalize the sale process of its remaining freezer asset, Custom Biogenic Systems (CBS).
• Management will discuss the company's financial results and provide a business update during a conference call and webcast.

Key Dates

Keywords

Cell Processing, Biopreservation Media, Cell and Gene Therapy, CGT, Biostorage Services, EBITDA, Gross Margin, Freezer Divestiture, Financial Results, Revenue Guidance